Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Completed · Phase 4

Conditions studied: Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)

In brief

To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

Key facts

Study ID

NCT00087490

Run by

Pfizer

People needed

1077

Starts

2004-10-01

Expected to finish

2007-07-01

Last updated by the study team

2012-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects with signs or symptoms consistent with infection, and if available, laboratory findings consistent with staphylococcal infection (e.g., Gram stain and culture results).
• Signs and symptoms consistent with infection
• Infection suspected to be due to Methicillin Resistant Staphylococcus Aureus

You may not qualify if…

• Subjects who were treated with a previous antibiotic (systemic or topical) with MRSA activity (other than linezolid or vancomycin) for more than 24 hours and treatment extended into the 72 hour period prior to the first dose of study drug, unless documented to be a treatment failure (72 hours of treatment and not responding).
• Subjects with uncomplicated skin or superficial skin structure infection such as superficial/simple cellulitis, impetiginous lesion, furuncle, or simple abscess that only need surgical drainage for cure.
• Subjects excluded with necrotizing fasciitis, gas gangrene, osteomyelitis

Where it is running

• Pfizer Investigational Site — Tucson, Arizona, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Palm Springs, California, United States
• Pfizer Investigational Site — Rancho Mirage, California, United States
• Pfizer Investigational Site — San Pedro, California, United States
• Pfizer Investigational Site — Santa Fe Springs, California, United States
• Pfizer Investigational Site — Sylmar, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Hartford, Connecticut, United States
• Pfizer Investigational Site — Hartford, Connecticut, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — Atlantis, Florida, United States
• Pfizer Investigational Site — Melbourne, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Pensacola, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Augusta, Georgia, United States
• Pfizer Investigational Site — Blue Ridge, Georgia, United States
• Pfizer Investigational Site — Honolulu, Hawaii, United States
• Pfizer Investigational Site — Montgomery, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.